CN Mobile Logo

Search form


All Content

In this interview we discuss the use of liquid biopsies in lung cancer, the pros and cons compared with tissue biopsies, and how they can be used to help make treatment decisions.

The PD-L1 inhibitor atezolizumab significantly improved overall survival compared with docetaxel across subgroups of patients with non–small-cell lung cancer.

Pembrolizumab was associated with clinically meaningful improvements in health-related quality of life compared with platinum-based chemotherapy in NSCLC patients.

Whole exome and transcriptome sequencing found that the genomic landscape of estrogen receptor-positive metastatic breast cancer differs from that of primary tumors.

The addition of everolimus to fulvestrant was associated with more than a doubling of progression-free survival in women with metastatic hormone receptor–positive, HER2-negative breast cancer who were resistant to aromatase inhibitor therapy.

Patients treated with first-line ceritinib had a 45% reduction in the risk for progression of advanced ALK-positive NSCLC compared with chemotherapy.

Second-line treatment with osimertinib resulted in significantly better progression-free survival compared with chemotherapy alone in patients with EGFR-T790M positive NSCLC, according to the results of the AURA3 trial.

In this interview we discuss breast cancer prevention and risk assessments, including the questions these assessments aim to answer, what classifies someone as average or high risk, and appropriate next steps for patients who fall in these categories.

This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.

Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.


By clicking Accept, you agree to become a member of the UBM Medica Community.